BLASUBCUTANEOUSINJECTABLE
Approved
Feb 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) by Roche is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2019.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HERCEPTIN HYLECTA is a subcutaneous injection combining trastuzumab (a HER2-targeted monoclonal antibody) with hyaluronidase to enable rapid subcutaneous delivery. It treats HER2-positive breast cancer by antagonizing HER2/neu receptor signaling, offering patients a faster, more convenient alternative to intravenous trastuzumab administration.
$0.514MPart D
PeakProduct is in peak commercial stage with modest Part D utilization; career roles focus on manufacturing and operational excellence rather than expansion.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers
Started Feb 2026
150 enrolled
Healthy Male Participants
Why This Matters for Your Career
Worked on HERCEPTIN HYLECTA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.